title: Significantly Higher Peripheral Insulin-Like Growth Factor-1 Levels in Patients With Major Depressive Disorder or Bipolar Disorder Than in Healthy Controls: A Meta-Analysis and Review Under Guideline of PRISMA.
abstract: An increasing amount of research has focused on insulin-like growth factor-1 (IGF-1) because of multiple neurotrophic effects, including neurogenesis, remyelination, and synaptogenesis. In addition, IGF-1 can mediate an antidepressant effect in patients with major affective disorder, and its levels in the cerebrospinal fluid have been found to vary with antidepressant treatment. Furthermore, it has been proven to crossover the blood-brain barrier, with a reciprocal feedback loop being the central effect. However, recent studies have reported inconclusive findings about the role of IGF-1 in major affective disorder. The aim of the current study was to conduct a thorough meta-analysis of changes in peripheral IGF-1 levels in patients with major depressive disorder (MDD) or bipolar disorder (BD). We conducted a thorough literature search and compared peripheral IGF-1 levels in patients with MDD or BD and in healthy controls, and investigated clinical variables through meta-regression. Electronic research was conducted through platform of PubMed. We used inclusion criteria as clinical trials discussing comparisons of peripheral IGF-1 protein levels in patients with MDD or BD and those in healthy controls. We analyzed the cases from 9 studies with the random-effect model. The main finding was that peripheral IGF-1 levels in the patients were significantly higher than in the healthy controls (P < 0.001), with a significant inverse association with duration of illness (P = 0.03). In meta-analysis comparing peripheral IGF-1 levels in patients with BD or MDD before and after treatment, there was no significant change in peripheral IGF-1 levels after treatment (P = 0.092). The small numbers of studies and lack of correlation data with growth hormone in current studies are the main limitations of this meta-analysis. Our results indicated that peripheral IGF-1 levels may not be an indicator of disease severity, but may be a disease trait marker or an indicator of cognition. However, further investigations on the correlation between cognitive function and peripheral IGF-1 levels are needed to explore the role of IGF-1 in the pathophysiology of MDD and BD.
authors.affiliation: From the Department of Psychiatry, Tsyr-Huey Mental Hospital, Kaohsiung Jen-Ai's Home, Taiwan (K-YT, H-YW, C-KW, P-TT); Department of Neurology, E-Da Hospital, Kaohsiung, Taiwan (Y-WC); Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan (M-KW, P-YL); and Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan (P-YL).
authors.forename: Kun-Yu
authors.initials: KY
authors.lastname: Tu
authors.forename: Ming-Kung
authors.initials: MK
authors.lastname: Wu
authors.forename: Yen-Wen
authors.initials: YW
authors.lastname: Chen
authors.forename: Pao-Yen
authors.initials: PY
authors.lastname: Lin
authors.forename: Hung-Yu
authors.initials: HY
authors.lastname: Wang
authors.forename: Ching-Kuan
authors.initials: CK
authors.lastname: Wu
authors.forename: Ping-Tao
authors.initials: PT
authors.lastname: Tseng
mesh_terms: D001714:Bipolar Disorder / Q000097:blood*; D016022:Case-Control Studies; D003865:Major Depressive Disorder / Q000097:blood*; D005215:Fasting; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism*; D013997:Time Factors
chemical_list: D007334:Insulin-Like Growth Factor I
references.citation: Pharmacol Res. 2013 Jul;73:1-7
references.pmid: 23619527
references.citation: Biol Psychiatry. 1995 Sep 1;38(5):325-9
references.pmid: 7495927
references.citation: Br J Psychiatry. 1978 Nov;133:429-35
references.pmid: 728692
references.citation: Horm Res. 1990;33 Suppl 4:25-30
references.pmid: 2245967
references.citation: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Mar;155(1):19-26
references.pmid: 21475373
references.citation: Dev Neurobiol. 2010 Apr;70(5):384-96
references.pmid: 20186710
references.citation: Growth Horm IGF Res. 2014 Apr-Jun;24(2-3):54-9
references.pmid: 24461794
references.citation: Eur Neuropsychopharmacol. 2015 Jun;25(6):864-72
references.pmid: 25836355
references.citation: Front Psychiatry. 2013 Feb 04;4:3
references.pmid: 23382717
references.citation: Endocr Rev. 1993 Feb;14(1):20-39
references.pmid: 8491152
references.citation: Medicina (Kaunas). 2004;40(8):740-4
references.pmid: 15299990
references.citation: J Mol Med (Berl). 2004 Mar;82(3):156-62
references.pmid: 14647921
references.citation: Exp Diabesity Res. 2003 Oct-Dec;4(4):205-12
references.pmid: 14668044
references.citation: Psychoneuroendocrinology. 1997 Oct;22(7):493-503
references.pmid: 9373883
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:334-9
references.pmid: 23022671
references.citation: J Neurosci. 2000 Nov 15;20(22):8435-42
references.pmid: 11069951
references.citation: Psychoneuroendocrinology. 2013 Nov;38(11):2789-99
references.pmid: 24001941
references.citation: Eur Neuropsychopharmacol. 2014 Jun;24(6):890-6
references.pmid: 24507017
references.citation: Endocrinology. 1994 Nov;135(5):1753-61
references.pmid: 7525251
references.citation: Eur Neuropsychopharmacol. 2015 Oct;25(10):1622-30
references.pmid: 26123242
references.citation: Neuropsychopharmacology. 2007 Nov;32(11):2360-8
references.pmid: 17342171
references.citation: J Affect Disord. 2014 Aug;165:24-30
references.pmid: 24882173
references.citation: PLoS Med. 2009 Jul 21;6(7):e1000100
references.pmid: 19621070
references.citation: Pharmacopsychiatry. 2009 Jan;42(1):23-8
references.pmid: 19153943
references.citation: J Clin Psychopharmacol. 2011 Jun;31(3):390-2
references.pmid: 21532371
references.citation: J Neurosci. 2000 Apr 15;20(8):2896-903
references.pmid: 10751442
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: Cell Mol Life Sci. 2014 Jan;71(1):21-42
references.pmid: 23543251
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:29-33
references.pmid: 23337034
references.citation: Psychol Bull. 2014 May;140(3):774-815
references.pmid: 24417575
references.citation: Pharmacol Rep. 2013;65(6):1622-31
references.pmid: 24553010
references.citation: Clin Epigenetics. 2011 Oct 26;3:2
references.pmid: 22414206
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Eur Neuropsychopharmacol. 2013 Oct;23(10):1199-207
references.pmid: 23183131
references.citation: N Engl J Med. 1996 Oct 17;335(16):1176-81
references.pmid: 8815939
references.citation: Mol Psychiatry. 2016 Feb;21(2):216-28
references.pmid: 26194180
references.citation: Clin Interv Aging. 2008;3(4):659-65
references.pmid: 19281058
references.citation: J Psychiatr Res. 1999 Mar-Apr;33(2):121-7
references.pmid: 10221744
references.citation: J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
references.pmid: 14399272
references.citation: Mol Cell Endocrinol. 1998 May 25;140(1-2):95-9
references.pmid: 9722175
references.citation: Acta Psychiatr Scand. 1988 Dec;78(6):684-8
references.pmid: 3223325
references.citation: Med Hypotheses. 2012 Aug;79(2):222-5
references.pmid: 22626951
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: J Clin Psychiatry. 2011 Aug;72(8):1124-8
references.pmid: 21208596
references.citation: Neuropharmacology. 2006 Dec;51(7-8):1129-36
references.pmid: 16919686
references.citation: Br J Clin Pharmacol. 2001 Apr;51(4):317-24
references.pmid: 11318766
references.citation: Eur J Endocrinol. 2002 Aug;147(2):165-71
references.pmid: 12153736
references.citation: Am J Med Genet B Neuropsychiatr Genet. 2011 Mar;156(2):177-87
references.pmid: 21302346
references.citation: Psychoneuroendocrinology. 2015 Apr;54:31-40
references.pmid: 25678185
references.citation: Neuropsychiatr Dis Treat. 2015 Apr 01;11:925-33
references.pmid: 25897228
references.citation: J Neurosci. 1993 Dec;13(12):5092-104
references.pmid: 7504720
references.citation: Eur J Pain. 2014 Mar;18(3):447-54
references.pmid: 25764228
references.citation: Psychoneuroendocrinology. 2014 Apr;42:118-23
references.pmid: 24636508
references.citation: J Affect Disord. 2013 Nov;151(2):738-743
references.pmid: 24012102
references.citation: Brain Res. 2007 May 25;1147:213-7
references.pmid: 17395163
references.citation: Psychiatry Res. 2014 Aug 15;218(1-2):54-60
references.pmid: 24793757
references.citation: Neurology. 2010 Jul 6;75(1):57-63
references.pmid: 20603485